Biocon launches Yesafili in US to treat opthalmology conditions

The product was earlier approved and granted interchangeable designation byt he US Food and Drug Administration (USFDA) in May 2024, allowing substitution at the pharmacy level in accordance with state laws, Biocon said.

Leave a Reply

Your email address will not be published. Required fields are marked *